ExodusPoint Capital Management LP Grows Stock Position in Elanco Animal Health Incorporated $ELAN

ExodusPoint Capital Management LP lifted its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 180.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 763,331 shares of the company’s stock after buying an additional 491,617 shares during the period. ExodusPoint Capital Management LP’s holdings in Elanco Animal Health were worth $17,274,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of ELAN. UBS Group AG increased its holdings in shares of Elanco Animal Health by 56.7% in the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after buying an additional 5,961,457 shares during the period. Artemis Investment Management LLP purchased a new position in shares of Elanco Animal Health in the fourth quarter worth about $55,693,000. Goldman Sachs Group Inc. increased its holdings in shares of Elanco Animal Health by 104.5% in the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after buying an additional 2,445,872 shares during the period. Bowen Hanes & Co. Inc. purchased a new position in shares of Elanco Animal Health in the third quarter worth about $47,626,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Elanco Animal Health by 3,682.0% in the fourth quarter. BNP Paribas Financial Markets now owns 2,252,961 shares of the company’s stock worth $50,985,000 after buying an additional 2,193,391 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on ELAN shares. Leerink Partners lifted their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Tuesday, February 24th. KeyCorp lifted their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Weiss Ratings downgraded Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. UBS Group restated a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Finally, Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $28.20.

Insider Buying and Selling

In related news, insider Rajeev A. Modi purchased 4,911 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were purchased at an average cost of $20.35 per share, with a total value of $99,938.85. Following the transaction, the insider directly owned 160,812 shares in the company, valued at $3,272,524.20. This trade represents a 3.15% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jeffrey N. Simmons acquired 4,971 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was acquired at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the transaction, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. This represents a 2.98% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 1.14% of the company’s stock.

Elanco Animal Health Stock Down 0.2%

Shares of NYSE:ELAN opened at $24.23 on Wednesday. Elanco Animal Health Incorporated has a 1 year low of $13.15 and a 1 year high of $27.72. The company has a market cap of $12.10 billion, a PE ratio of -48.46, a P/E/G ratio of 1.59 and a beta of 1.69. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12. The stock’s 50-day moving average is $22.95 and its 200 day moving average is $23.49.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter in the prior year, the business earned $0.37 EPS. The business’s revenue for the quarter was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Sell-side analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.